IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS...

Hematological Oncology 2017 / 06 Vol. 35

IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY

Rule, S., Jurczak, W., Jerkeman, M., Santucci Silva, R., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S., Thieblemont, C., Zhou,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2437_133
Date:
June, 2017
File:
PDF, 164 KB
english, 2017
Conversion to is in progress
Conversion to is failed